Physician profile
Yazan Abdullah
NPI 1194110676
$13,306.70
in general payments reported to CMS, 2019-2025
27 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,562 · 2020: $2,476 · 2021: $1,922 · 2022: $1,499 · 2023: $2,041 · 2024: $1,673 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,847.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,231.79 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $2,707.35 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Merck Sharp & Dohme LLC | $1,258.65 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Janssen Biotech, INC. | $900.21 | 2019-2021 | |
| Emd Serono, INC. | $587.14 | 2019-2020 | |
| Allergan, INC. | $371.60 | 2019-2020 | |
| Amgen INC. | $363.96 | 2019-2022 | |
| Napo Pharmaceuticals INC | $268.84 | 2019-2020 | |
| Astellas Pharma US INC | $242.88 | 2019-2021 | |
| Eisai INC. | $183.74 | 2020-2022 | |
| Amarin Pharma, INC. | $172.07 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.71 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $117.04 | 2020-2021 | |
| Abbvie INC. | $115.69 | 2021-2022 | |
| Melinta Therapeutics, LLC | $87.06 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyera Pharmaceuticals, LLC | $76.02 | 2019-2021 | |
| Antares Pharma, INC. | $66.37 | 2019-2022 | |
| Theratechnologies INC. | $64.32 | 2020-2021 | |
| Lilly USA, LLC | $59.58 | 2020 | |
| Philips North America LLC | $54.54 | 2019-2020 | |
| Daiichi Sankyo INC. | $51.68 | 2019-2021 | |
| Tetraphase Pharmaceuticals, INC. | $42.37 | 2020 | |
| Nabriva Therapeutics, Plc | $37.79 | 2020 | |
| Tactile Systems Technology INC | $29.68 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Galderma Laboratories, L.P. | $18.19 | 2022 | |
| Janssen Scientific Affairs, LLC | $17.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yazan Abdullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.